Therapeutic
Peptides that treat named conditions with real clinical trials behind them. Insulin. GLP-1 agonists. Oxytocin. FDA-approved bremelanotide.
Short chains of amino acids. Some heal tissue, some tune receptors, some do very little. The internet treats them like magic. This does not.
A peptide is a short chain of amino acids linked by covalent bonds — the same chemistry that builds every protein in your body, just at a smaller scale. The convention is fuzzy, but most biochemists call anything under about fifty residues a peptide. Above that, you call it a protein.
Every one of the twenty canonical amino acids has the same backbone — an amino group on one end, a carboxyl on the other, a central carbon holding a unique side chain. When two amino acids meet, water leaves and a peptide bond forms. Do this a handful of times and you've built a signalling molecule. Do it hundreds of times, you've built an enzyme.
The short length matters. Small peptides slip through membranes, fold quickly, bind receptors with precision, and — when their job is done — break apart just as easily. That disposability is the point: they ferry signals, trigger cascades, and get recycled.
A peptide finds its receptor — a specific protein on the cell's surface — and latches on. The receptor's shape dictates which peptides it will accept; the fit is as specific as a key in a lock. Nothing else has happened yet.
Binding changes the receptor's shape, which triggers a chain of events on the cell's interior — G-proteins activate, enzymes switch on, second messengers flood the cytoplasm. The peptide itself stays outside; it only delivered a message.
The signalling cascade changes what the cell is doing — genes transcribed, proteins made, enzymes unleashed, structures built. Minutes to hours later, you see the effect: tissue heals, appetite shifts, skin remodels, sleep deepens. Then the peptide is cleared, and the system resets.
Peptides that treat named conditions with real clinical trials behind them. Insulin. GLP-1 agonists. Oxytocin. FDA-approved bremelanotide.
The muscle-and-tendon class. BPC-157, TB-500, thymosin. Rich in animal data, thin on rigorous human trials, popular with athletes.
Peptides that nudge the pituitary into releasing growth hormone — ipamorelin, sermorelin, CJC-1295. Effects real, marketing noisier than the evidence.
Signals aimed at the nervous system. Semax, Selank, oxytocin. Russian labs have decades of clinical use; the West is slower to catch up.
Skin-surface peptides — GHK-Cu, Matrixyl, argireline. Mostly topical, with better evidence than the average marketed supplement.
Each card lists the peptide, its sequence, its claimed effect, and — the part most sites skip — the evidence tier and a plain note about what the evidence actually shows.
GEPPPGKPADDAGLVAccelerates healing of tendons, ligaments, muscle, and gut lining. Anti-inflammatory. Marketed as a universal repair aid.
The bulk of published BPC-157 research traces back to one group in Zagreb. Independent replication at the same scale is missing. Human trials are essentially absent. Banned by WADA. Plausible mechanism, compelling rat data, but the single-lab problem is real.
Gly-His-Lys + Cu²⁺Stimulates collagen synthesis, improves skin texture, accelerates wound healing. The old-guard cosmetic peptide.
Among the best-supported peptides for topical use — decades of research, multiple independent groups, real cosmetic studies. Claims beyond skin (systemic anti-aging, organ repair) are extrapolated from in-vitro work and should be treated skeptically.
LKKTETQ (partial)Tissue repair, cell migration, angiogenesis. Borrows reputation from the full thymosin β4 molecule (which has real research).
Fragment does not equal parent molecule. Most TB-500 claims rely on evidence for full-length thymosin β4. The fragment itself has much thinner support. Watch for marketing that quietly swaps the two.
Ala-Glu-Asp-GlyActivates telomerase, extends lifespan, restores circadian rhythm. The anti-aging peptide with the boldest claims.
Nearly all positive data comes from Vladimir Khavinson's St. Petersburg group. Strong claims — lifespan extension, telomere elongation — with no replication outside Russia. Treat with the same skepticism you'd give any single-lab story.
Met-Glu-His-Phe-Pro-Gly-ProCognitive enhancement, stroke recovery, neuroprotection. Intranasal use; approved in Russia as a clinical drug.
Strongest clinical base of any peptide on this page — decades of Russian hospital use, real stroke-recovery trials, established safety profile. Western replication is thin, regulatory status outside Russia is nonexistent. Evidence is real, jurisdiction limited.
Ac-Nle-Asp-His-D-Phe-Arg-Trp-Lys-OHIncreases sexual arousal via central melanocortin receptors. FDA-approved for premenopausal HSDD as Vyleesi.
The only specimen on this page with full regulatory approval and multiple independent Phase 3 trials. Mechanism is well-mapped. Side effects are real — nausea, hypertension, skin darkening at injection site. Effect is modest but statistically reliable.
Not all evidence counts equally. A good habit — before trusting any peptide claim — is to find the strongest study actually cited and ask where on the pyramid below it sits.
Most peptide marketing cites in-vitro work or animal studies and leaves readers to assume those results would translate to a human. They often don't. The higher on the pyramid, the more confident you can be.
The peptides on the previous page sit everywhere on this pyramid. Bremelanotide is tier I. Semax is tier II. BPC-157, TB-500, and Epithalon sit at tier IV — and the single-lab asterisk means you should discount them further.